Page 2 of 3
123

2014 (2 POSTS)

Christian WV, Oliver LD, Paustenbach DJ, Kreider ML, Finley BL. 2014. Toxicology-based cancer causation analysis of CoCr-containing hip implants: A quantitative assessment of genotoxicity and tumorigenicity studies. J Appl Toxicol 34(9):939–967; doi: 10.1002/jat.3039.

View Abstract

2013 (2 POSTS)

Sutter A, Amberg A, Boyer S, Brigo A, Contrera JF, Custer LL, Dobo KL,…, Greene N, et al. 2013. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul Toxicol Pharmacol 67(1):39-52; doi: 10.1016/j.yrtph.2013.05.001. PMID: 23669331.

View Abstract

Urban JD, Carakostas MC, Brusick DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51(Jan):386-390; doi: 10.1016/j.fct.2012.10.016.

View Abstract

2012 (7 POSTS)

Naven RT, Greene N, Williams RV. 2012. Latest advances in computational genotoxicity prediction. Exp Opin Drug Metabol 8(12):1579-87; doi: 10.1517/17425255.2012.724059. PMID: 22998164.

View Abstract

Schmitt D, Tran N, Peach J, Bauter M, Marone P. 2012. Toxicologic evaluation of DHA-rich algal oil: Genotoxicity, acute and subchronic toxicity in rats. Food Chem Toxicol 50(10):3567–3576; doi: 10.1016/j.fct.2012.07.054. PMID: 22898615.

View Abstract

Harris MA, Thompson CM, Wolf JC, Fedorov Y, Hixon JG, Proctor DM, Suh M, Haws LC. Assessment of genotoxic potential of Cr(VI) in the intestine via in vivo intestinal micronucleus assay and in vitro high content analysis in differentiated and undifferentiated caco-2. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

View Abstract

Thompson CM, Fedorov Y, Brown DD, Suh MProctor DM, Kuriakose L, Haws L, Harris MA. 2012. Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis. PLoS ONE 7(8):e42720; doi: 10.1371/journal.pone.0042720.

View Abstract

Thompson CM, Hixon JG, Proctor DM, Haws LC, Suh M, Urban JD, Harris MA. 2012. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul Toxicol Pharmacol 64(1):68-76; doi: 10.1016/j.yrtph.2012.05.019

View Abstract

Dobo KL, Greene N, Fred C, Glowienke S, Harvey JS, Hasselgren C, Jolly R, Kenyon MO, et al. 2012. In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey. Regul Toxicol Pharmacol 62(3):449-455; doi: 10.1016/j.yrtph.2012.01.007. PMID: 22321701.

View Abstract

Thompson CM, Hixon JG, Kopec AK, Harris MA, Proctor DM, Haws LC. Assessment of genotoxic potential of Cr(VI) in the mouse duodenum via toxicogenomic profiling. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

View Abstract

2011 (3 POSTS)

Robison TW. 2011. Dealing with positive in vitro mammalian cell genotoxicity assays. Inter Drug Discovery 6(5):40-43.

View Abstract

Tichomirowa MA, Bariler A, Daly AF, Jaffrain-Rea M-L, Ronchi CL, Yaneva M, Urban JD, Petrossians P, et al. 2011. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509-515; doi: 10.1530/EJE-11-0304. PMID: 21753072.

View Abstract

Grace CE, Kim SJ, Rogers JM. 2011. Maternal influences on epigenetic programming of the developing hypothalamic-pituitary-adrenal axis. Birth Defects Res A 91(8):797–805; doi: 10.1002/bdra.20824. PMID: 21656659.

View Abstract

2010 (7 POSTS)

Robison TW. Genotoxic impurity guidance – Current experiences, FDA perspective. USP Annual Meeting, New Orleans, LA, December 2010.

Chen F, Smith R, Gu YZ, Collins ND, Nioi P. 2010. Toxicoepigenetic alteration of the Kidney Injury Molecule 1 gene in gentamicin-exposed rat kidney. Toxicol Sci 117(2):375–380; doi: 10.1093/toxsci/kfq202. PMID: 20660082.

View Abstract

Robison TW. Dealing with positive in vitro mammalian cell genotoxicity assays. IQPC Genotoxicity and Carcinogenicity Testing 2010 Conference, London, UK, October 2010.

Robison TW. Dealing with genotoxic impurities from a regulatory perspective. IQPC Genotoxicity and Carcinogenicity Testing 2010 Conference, London, UK, October 2010.

Robison TW. Assessing genotoxic impurities. DIA Meeting (Early drug development: Navigating the treacherous rapids). Bethesda, MD, October 2010

Naven RT, Louise-May S, Greene N. 2010. The computational prediction of genotoxicity. Exp Opin Drug Metabol Toxicol 6(7):1-11; doi: 10.1517/17425255.2010.495118. PMID: 20528613.

View Abstract

Waters MD, Jackson MA, Lea IA. 2010. Characterizing and predicting carcinogenicity and mode-of-action using conventional and toxicogenomics methods. Mutat Res 705(3):184–200; doi: 10.1016/j.mrrev.2010.04.005.

View Abstract
Page 2 of 3
123